Aptevo Therapeutics Inc. Operating Cash Flow
Aptevo Therapeutics Inc. (APVO) reported Operating Cash Flow of -$13.42 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- Aptevo Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$5.45M.
- Aptevo Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$7.96M.
- Aptevo Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$5.24M.
- Aptevo Therapeutics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$6.69M.
- Aptevo Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$25.59M.
- Aptevo Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$23.79M.
- Aptevo Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$11.73M.
- Aptevo Therapeutics Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$21.02M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$13.42M 10-Q · filed 2026-08-14 | -$18.66M derived: sum of 3 quarters · filed 2026-08-14 | -$25.34M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$7.96M 10-Q · filed 2026-05-13 | -$13.20M derived: sum of 2 quarters · filed 2026-05-13 | -$19.89M derived: sum of 3 quarters · filed 2026-05-13 | -$26.98M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$5.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$11.92M derived: sum of 2 quarters · filed 2026-03-26 | -$19.02M derived: sum of 3 quarters · filed 2026-08-14 | -$25.59M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$6.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$13.78M derived: sum of 2 quarters · filed 2026-08-14 | -$20.36M 10-Q · filed 2025-11-06 | -$26.11M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$7.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$13.67M 10-Q · filed 2026-08-14 | -$19.43M derived: sum of 3 quarters · filed 2026-08-14 | -$24.65M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$6.58M 10-Q · filed 2026-05-13 | -$12.33M derived: sum of 2 quarters · filed 2026-05-13 | -$17.56M derived: sum of 3 quarters · filed 2026-05-13 | -$23.71M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$5.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$10.98M derived: sum of 2 quarters · filed 2026-03-26 | -$17.13M derived: sum of 3 quarters · filed 2026-03-26 | -$23.79M 10-K · filed 2026-03-26 |
| 2024-09-30 | -$5.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$11.38M derived: sum of 2 quarters · filed 2025-11-06 | -$18.03M 10-Q · filed 2025-11-06 | -$23.28M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$6.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$12.80M 10-Q · filed 2025-08-11 | -$18.06M derived: sum of 3 quarters · filed 2025-08-11 | -$24.30M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$6.65M 10-Q · filed 2025-05-15 | -$11.90M derived: sum of 2 quarters · filed 2025-05-15 | -$18.14M derived: sum of 3 quarters · filed 2025-05-15 | -$22.95M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$5.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | -$11.49M derived: sum of 2 quarters · filed 2025-02-14 | -$16.30M derived: sum of 3 quarters · filed 2025-02-14 | -$11.73M 10-K · filed 2025-02-14 |
| 2023-09-30 | -$6.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$11.04M derived: sum of 2 quarters · filed 2024-11-07 | -$6.48M 10-Q · filed 2024-11-07 | -$12.42M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$4.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$237.00K 10-Q · filed 2024-08-08 | -$6.18M derived: sum of 3 quarters · filed 2024-08-08 | -$13.07M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $4.57M 10-Q · filed 2024-05-08 | -$1.37M derived: sum of 2 quarters · filed 2024-05-08 | -$8.27M derived: sum of 3 quarters · filed 2024-05-08 | -$11.34M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$5.94M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$12.84M derived: sum of 2 quarters · filed 2024-03-05 | -$15.90M derived: sum of 3 quarters · filed 2024-03-05 | -$21.02M 10-K · filed 2024-03-05 |
| 2022-09-30 | -$6.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$9.97M derived: sum of 2 quarters · filed 2023-11-14 | -$15.08M 10-Q · filed 2023-11-14 | -$18.96M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$3.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$8.19M 10-Q · filed 2023-08-10 | -$12.07M derived: sum of 3 quarters · filed 2023-08-10 | -$17.31M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$5.12M 10-Q · filed 2023-05-11 | -$9.00M derived: sum of 2 quarters · filed 2023-05-11 | -$14.24M derived: sum of 3 quarters · filed 2023-05-11 | -$19.29M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$3.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$9.12M derived: sum of 2 quarters · filed 2023-03-30 | -$14.18M derived: sum of 3 quarters · filed 2023-03-30 | -$21.68M 10-K · filed 2023-03-30 |
| 2021-09-30 | -$5.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$10.29M derived: sum of 2 quarters · filed 2022-11-10 | -$17.80M 10-Q · filed 2022-11-10 | -$23.92M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$5.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$12.56M 10-Q · filed 2022-08-11 | -$18.68M derived: sum of 3 quarters · filed 2022-08-11 | -$26.07M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$7.50M 10-Q · filed 2022-05-12 | -$13.63M derived: sum of 2 quarters · filed 2022-05-12 | -$21.01M derived: sum of 3 quarters · filed 2022-05-12 | -$25.65M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | -$6.12M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | -$13.51M derived: sum of 2 quarters · filed 2022-03-24 | -$18.14M derived: sum of 3 quarters · filed 2022-03-24 | -$29.32M 10-K · filed 2022-03-24 |
| 2020-09-30 | -$7.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$12.02M derived: sum of 2 quarters · filed 2021-11-12 | -$23.20M 10-Q · filed 2021-11-12 | -$28.30M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | -$4.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$15.81M 10-Q · filed 2021-08-12 | -$20.91M derived: sum of 3 quarters · filed 2021-08-12 | -$28.46M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | -$11.18M 10-Q · filed 2021-05-11 | -$16.27M derived: sum of 2 quarters · filed 2021-05-11 | -$23.82M derived: sum of 3 quarters · filed 2021-05-11 | -$39.71M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | -$5.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$12.65M derived: sum of 2 quarters · filed 2021-03-31 | -$28.54M derived: sum of 3 quarters · filed 2021-03-31 | -$42.38M 10-K · filed 2021-03-31 |
| 2019-09-30 | -$7.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$23.44M derived: sum of 2 quarters · filed 2020-11-10 | -$37.28M 10-Q · filed 2020-11-10 | -$44.58M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | -$15.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | -$29.73M 10-Q · filed 2020-08-14 | -$37.03M derived: sum of 3 quarters · filed 2020-08-14 | -$48.17M derived: sum of 4 quarters · filed 2020-08-14 |
| 2019-03-31 | -$13.84M 10-Q · filed 2020-05-13 | -$21.14M derived: sum of 2 quarters · filed 2020-05-13 | -$32.28M derived: sum of 3 quarters · filed 2020-05-13 | -$48.29M derived: sum of 4 quarters · filed 2020-05-13 |
| 2018-12-31 | -$7.29M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | -$18.44M derived: sum of 2 quarters · filed 2020-03-25 | -$34.44M derived: sum of 3 quarters · filed 2020-03-25 | -$51.42M 10-K · filed 2020-03-25 |
| 2018-09-30 | -$11.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | -$27.15M derived: sum of 2 quarters · filed 2019-11-07 | -$44.13M 10-Q · filed 2019-11-07 | -$59.55M derived: sum of 4 quarters · filed 2019-11-07 |
| 2018-06-30 | -$16.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$32.98M 10-Q · filed 2019-08-09 | -$48.41M derived: sum of 3 quarters · filed 2019-08-09 | -$50.02M derived: sum of 4 quarters · filed 2019-08-09 |
| 2018-03-31 | -$16.98M 10-Q · filed 2019-05-09 | -$32.40M derived: sum of 2 quarters · filed 2019-05-09 | -$34.02M derived: sum of 3 quarters · filed 2019-05-09 | |
| 2017-12-31 | -$15.42M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | -$17.04M derived: sum of 2 quarters · filed 2019-03-18 | -$41.57M 10-K · filed 2019-03-18 | |
| 2017-09-30 | -$1.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | -$26.15M 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | -$24.54M 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B |